

IN THE CLAIMS:

Please substitute amended claim 6 for the pending claim having the same claim number.

Please add for consideration new claim numbers 13 to 17.

1. (Withdrawn) A method for enhancing the development of a cellular immune response to a preselected antigen in a mammal comprising exposing ex vivo or in vivo dendritic cells from said mammal to a conjugate comprising said preselected antigen covalently bound to an antibody to DEC-205, and promoting maturation of said dendritic cells ex vivo or in vivo by CD40 ligation.
2. (Withdrawn) The method of claim 1 wherein said preselected antigen is a peptide antigen or a protein antigen.
3. (Withdrawn) The method of claim 3 wherein said peptide antigen or protein antigen is conjugated to said antibody to DEC-205 by means of a cross-linking agent.
4. (Withdrawn) The method of claim 2 wherein a light chain or a heavy chain of said antibody to DEC-205, and said peptide antigen or protein antigen, are present on a single polypeptide chain.
5. (Withdrawn) The method of claim 1 wherein said CD40 ligation is achieved by exposing said dendritic cell to an agonistic anti-CD40 antibody.
6. (currently amended) A method for enhancing the development of tolerance to a preselected antigen for which tolerance is desired, in a mammal comprising exposing ex vivo or in vivo dendritic cells from said mammal to a conjugate comprising said preselected antigen covalently bound to an anti-human DEC-205 antibody or an anti-murine DEC-205 antibody that binds to human DEC-205 under conditions that promote dendritic cell quiescence, said human DEC-205 protein comprising an amino acid

sequence as set forth in SEQ ID NOs: 8 and 9 NO: 7, and wherein said preselected antigen is selected from the group consisting of allergens, autoantigens and antigens participating in allograft rejection.

7. (Original) The method of claim 6 wherein said preselected antigen is a peptide antigen or a protein antigen.

8. (Original) The method of claim 7 wherein said peptide or protein is conjugated to said antibody to DEC-205 by means of a cross-linking agent.

9. (Original) The method of claim 7 wherein a light chain or a heavy chain of said antibody to DEC-205, and said peptide antigen or protein antigen, are present on a single polypeptide chain.

10. (Withdrawn) A conjugate for enhanced delivery of a preselected protein or peptide antigen to a dendritic cell, said conjugate comprising said preselected protein or peptide antigen covalently bound to an antibody to DEC-205.

11. (Withdrawn) The conjugate of claim 10 wherein a light chain or a heavy chain of said antibody to DEC-205, and said peptide antigen or protein antigen, are present on a single polypeptide chain.

12. (Withdrawn) A method for enhancing the delivery of a preselected molecule into a dendritic cell comprising the steps of preparing a conjugate comprising said preselected molecule and an antibody to DEC-205, and exposing said conjugate to a dendritic cell, wherein said conjugate is delivered into said dendritic cell.

13. (new) A method for enhancing the development of tolerance to a preselected antigen for which tolerance is desired in a mammal, comprising exposing ex vivo or in vivo dendritic cells from said mammal to a conjugate comprising said preselected antigen covalently bound to an anti-human DEC-205 antibody, wherein the antibody is reactive

with an amino acid sequence as set forth in SEQ ID NO: 7, under conditions that promote dendritic cell quiescence, wherein said preselected antigen is selected from the group consisting of allergens, autoantigens and antigens participating in allograft rejection.

14. (new) A method for enhancing the development of tolerance to a preselected antigen for which tolerance is desired, in a mammal comprising exposing ex vivo or in vivo dendritic cells from said mammal to a conjugate comprising said preselected antigen covalently bound to an anti-murine DEC-205 antibody, wherein the antibody is reactive with an amino acid sequence as set forth in SEQ ID NO: 7, under conditions that promote dendritic cell quiescence, and wherein said preselected antigen is selected from the group consisting of allergens, autoantigens and antigens participating in allograft rejection.

15. (new) The method of either one of claims 13 or 14, wherein said preselected antigen is a peptide antigen or a protein antigen.

16. (new) The method of either one of claims 13 or 14, wherein said peptide or protein antigen is conjugated to said antibody to DEC-205 by means of a cross-linking agent.

17. (new) The method of either one of claims 13 or 14, wherein a light chain or a heavy chain of said antibody to DEC-205, and said peptide antigen or protein antigen, are present on a single polypeptide chain.